In 2010, it was estimated that more than 200 million people worldwide were living with peripheral arterial disease. Chronic limb-threatening ischemia (CLTI) represents the end stage of peripheral arterial disease, which, left untreated, incurs a risk of major amputation, approaching 25% at 1 year. Despite the global scale and severe clinical consequences of CLTI, it has been poorly defined and variably managed. Prior guidelines, such as the Trans-atlantic Inter-society Consensus Document on the Management of Peripheral Arterial Disease (TASC II), have offered treatment recommendations based on disease anatomy alone.1 A more contemporary, nuanced definition of the problem and thorough understanding of the state of evidence are required to guide medical treatment, revascularization strategies, and future study.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jones DW, Farber A. Review of the Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. JAMA Surg. 2020;155(2):161–162. doi:10.1001/jamasurg.2019.4928
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.